Alan L. Ho MD, PhD is a medical oncologist on the solid tumor service at Memorial Sloan Kettering Cancer Center. He did his undergraduate work at Washington University School of Medicine and Medical School at Stanford University, where he graduated Phi Beta Kappa. He did his Residency at Weill Cornell-NY Presbyterian and Fellowship at MSKCC. He specializes in the management of head and neck squamous cell carcinomas, thyroid cancers, salivary cancers, and non-melanoma skin cancers. His research is focused upon the translational science of developing novel therapeutics for these malignancies. He is the principal investigator (PI) of two NIH R01s and a co-PI in the MSK Thyroid Cancer Spore program. He is a member of the Experimental Therapeutics Committee in the Alliance for Clinical Trials in Oncology, and has served as the national PI of an NCI-cooperative group trial. Dr. Ho is currently the National Translational PI of the NCI MATCH clinical trial effort evaluating a hedgehog pathway inhibitor. He serves as a co-chair of the head and neck subsection of the International Clinical Trials in Rare Cancers Initiative and is a member of the National Comprehensive Cancer Network (NCCN) practice guidelines committee for the management of non-melanoma skin cancers. He is also the current chair of the MSK Investigational New Drug committee.